Medgenics Announces Results of 2013 Annual Meeting of Stockholders

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”),, the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company’s Annual Meeting of Stockholders held yesterday were duly passed.

Each of the current directors of the Company, Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr. Joseph J. Grano, Jr., Mr. Joel S. Kanter, Dr. Stephen D. McMurray and Dr. Andrew L. Pearlman, was reelected to the Board of Directors.

Stockholders also approved an amendment of the Company’s Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan by 1,700,000 shares.

Stockholders also approved, on an advisory basis, the compensation of the executive officers of the Company. Additionally, the option to request the stockholders to vote, on an advisory basis, on executive compensation every three years received the most votes cast.

Stockholders also ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2013.

Final voting tallies are subject to certification by the Company's inspector of elections and will be included in the Company's report, which is to be filed with the Securities and Exchange Commission within the next week.

About Medgenics

Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.